Physician profile
Albert Joseph
NPI 1518051499
$3,911.69
in general payments reported to CMS, 2019-2025
28 companies · $654 in 2025
The $654 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $454 · 2021: $534 · 2022: $548 · 2023: $545 · 2024: $656 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $738.42 | 2019-2025 | Capvaxive, Verquvo, Gardasil 9 |
| Novo Nordisk INC | $716.75 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $407.98 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $281.84 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $217.86 | 2019-2022 | |
| Exact Sciences Corporation | $157.65 | 2024-2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $148.42 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $144.49 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $138.43 | 2019-2025 | Jardiance |
| Philips North America LLC | $135.17 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $112.06 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.09 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $85.60 | 2019-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $82.16 | 2021-2022 | |
| Abbott Laboratories | $65.72 | 2023-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $59.94 | 2023-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $57.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.95 | 2019-2022 | |
| Mylan Specialty L.P. | $48.65 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $35.95 | 2023-2024 | Spravato, Xarelto |
| Viatris Specialty LLC | $19.40 | 2025 | Yupelri |
| Dexcom, INC. | $17.23 | 2025 | Dexcom G6 Transmitter |
| Lexicon Pharmaceuticals, INC. | $16.57 | 2024 | |
| Scilex Pharmaceuticals INC. | $15.77 | 2024 | |
| Axsome Therapeutics, INC. | $14.28 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.13 | 2022 | |
| Abbvie INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.